Tyra Biosciences, Inc.

Tyra Biosciences is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company utilizes its proprietary in-house precision medicine platform, SNÅP, to enable rapid and precise structural drug design, aiming to overcome mechanisms of resistance in cancer and address genetically defined conditions. The company's pipeline is centered on small-molecule inhibitors designed to be potent and selective, addressing limitations of first-generation therapies. Their lead candidate, dabogratinib, is currently being evaluated for skeletal dysplasias (including achondroplasia) and various urologic cancers, including non-muscle invasive bladder cancer (NMIBC) and low-grade upper tract urothelial cancer (LG-UTUC).